# Characteristics and Outcomes of IBD Patients with COVID-19 on Tofacitinib Therapy in the SECURE-IBD Registry

Manasi Agrawal, MD, \*• Erica J. Brenner, MD,<sup>†</sup> Xian Zhang, PhD,<sup>†</sup> Irene Modesto, MD, PhD,<sup>‡</sup> John Woolcott, PhD,<sup>‡</sup> Ryan C. Ungaro, MD, MS,<sup>\*</sup> Jean-Frederic Colombel, MD,<sup>\*</sup> and Michael D. Kappelman, MD, MPH<sup>†</sup>

Key Words: inflammatory bowel disease, Crohn's disease; ulcerative colitis, coronavirus disease 2019, tofacitinib, outcomes

## INTRODUCTION

The coronavirus disease 2019 (COVID-19) pandemic due to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to unprecedented loss of life and health on a global scale.<sup>1</sup> COVID-19 outcomes are more severe among those with comorbid conditions,<sup>1</sup> which raises concerns for patients with inflammatory bowel disease (IBD), especially given the increased infection risk with immunosuppression used for IBD therapy.

Tofacitinib is a Janus kinase inhibitor (JAKi) approved for the treatment of ulcerative colitis (UC)<sup>2</sup> and other immunemediated diseases. Tofacitinib is associated with higher risk of herpes zoster (HZ) infection.<sup>2</sup> Although HZ is a DNA virus, little is known regarding risks and outcomes of RNA viral infections such as SARS-CoV-2 with JAKi. Type 1 interferons, central to anti-SARS-CoV-2 activity and induced by the JAK-STAT pathway, were found to be impaired in severe COVID-19 in some studies and conversely upregulated in others, possibly reflecting heterogeneity in COVID-19 severity.<sup>3</sup> Emerging data

Received for publications October 16, 2020; Editorial Decision November 3, 2020.

From the \*The Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York, USA; <sup>†</sup>Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA; <sup>‡</sup>Inflammation and Immunology, Global Medical Affairs, Pfizer Inc, New York, New York, USA.

Author Contribution: MA contributed to the study concept and design, interpretation of data, drafting of manuscript, and critical revision of the manuscript for important intellectual content. EJB and RCU contributed to the study concept and design, acquisition of data, interpretation of data, and critical revision of the manuscript for important intellectual content. XZ contributed to the acquisition, analysis, and interpretation of data. IM contributed to the study concept and design and critical revision of the manuscript for important intellectual content. JW contributed to the drafting of manuscript and critical revision of the manuscript for important intellectual content. JFC contributed to the study concept and design, interpretation of data, and critical revision of the manuscript for important intellectual content. MDK contributed to the study concept and design, interpretation of data, and critical revision of the manuscript for important intellectual content.

Supported by: This work was funded by the Helmsley Charitable Trust (2003–04445), National Center for Advancing Translational Sciences (UL1TR002489), a T32DK007634 (EJB), and a K23KD111995-01A1 (RCU). Additional funding provided by Pfizer, Takeda Pharmaceutical Company, Janssen Biotech., AbbVie Inc., Eli Lilly and Company, Genentech, Boehringer Ingelheim, Bristol Myers Squibb, Celtrion, and Arenapharm. The current analysis did not receive any direct funding from Pfizer.

Conflicts of Interest: MA receives research support from the Dickler Family Fund, New York Community Trust, and the Helmsley Charitable Trust Fund for SECURE-IBD. in non-IBD patients suggest that JAKi may blunt the cytokine storm that characterizes severe COVID-19 and potentially improve outcomes.<sup>4</sup> In fact, a number of JAKi such as tofacitinib, baricitinib and ruxolitinib are being studied in clinical trials for COVID-19 treatment.

Moreover, hospitalized COVID-19 patients are at a greater risk of thromboembolic events. This is important because findings from an interim analysis of a rheumatoid arthritis study for tofacitinib in older patients with  $\geq 1$  cardiovascular risk factor, alongside data from other JAKi clinical programs, suggest a higher risk of venous thromboembolic events.<sup>5</sup>

Emerging data on COVID-19 outcomes in patients with immune-mediated diseases treated with JAKi do not indicate worse outcomes compared with other immunosuppressive therapies; prior studies have been limited by very small sample sizes of fewer than 10 patients.<sup>6-9</sup> To address this critical knowledge gap, we analyzed characteristics and outcomes of tofacitinib-treated IBD patients with COVID-19 compared with those on other medications in a global registry.

EJB is supported by an Institutional Training Grant from the National Institutes of Health (T32DK007634). XZ reports no conflict of interest. IM and JW are employees and shareholders of Pfizer Inc. RCU has served as a consultant and/or advisory board member for Eli Lilly, Janssen, Pfizer, and Takeda; he has received research support from AbbVie, Boehringer Ingelheim, and Pfizer; he is supported by a Career Development Award from the National Institutes of Health (K23KD111995-01A1). JFC reports receiving research grants from AbbVie, Janssen Pharmaceuticals, and Takeda; receiving payment for lectures from AbbVie, Amgen, Allergan, Inc. Ferring Pharmaceuticals, Shire, and Takeda; receiving consulting fees from AbbVie, Amgen, Arena Pharmaceuticals, Boehringer Ingelheim, Celgene Corporation, Celltrion, Eli Lilly, Enterome, Ferring Pharmaceuticals, Genentech, Janssen Pharmaceuticals, Landos, Ipsen, Medimmune, Merck, Novartis, Pfizer, Shire, Takeda, Tigenix, and Viela bio; and holding stock options in Intestinal Biotech Development and Genfit. MDK has consulted for Abbvie, Janssen, Pfizer, and Takeda, is a shareholder in Johnson & Johnson, and has received research support from Pfizer, Takeda, Janssen, Abbvie, Lilly, Genentech, Boehringer Ingelheim, Bristol Myers Squibb, Celtrion, and Arenapharm. The corresponding author confirms on behalf of all authors that there have been no involvements that might raise the question of bias in the work reported or in the conclusions, implications, or opinions stated.

Address correspondence to: Manasi Agrawal, MD, The Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Place, New York, NY 10029, USA. E-mail: manasi.agrawal@mountsinai. org.

<b>Characteristic</b> <sup>a,b</sup>	All Patien	All Patients on ≥1 Medication		Tofacitinib	Othe	Other IBD Therapy	
	N (Mean)	% (SD)	N (Mean)	% (SD)	N (Mean)	% (SD)	Pc
Total number of patients	2326		37		2289		
Mean age	41.5	18.1	42.4	17.18	41.5	18.08	0.747
Median age (IQR)	39	27.0, 54.0	41	30.5, 55.0	39	27.0, 54.0	0.670
Female sex	1150	49.4%	15	40.5%	1135	49.6%	0.275
Race							
White	1840	79.1%	29	78.4%	1811	79.1%	0.913
Black or African American	158	6.8%	1	2.7%	157	6.9%	0.512
American Indian/Native Alaskan	4	0.2%	0	0.0%	4	0.2%	>0.999
Asian	132	5.7%	2	5.4%	130	5.7%	>0.999
Native Hawaiian/Pacific Islander	0	0.0%	0	0.0%	0	0.0%	
Other	175	7.5%	c.	8.1%	172	7.5%	0.755
Unknown	96	4.1%	ŝ	8.1%	93	4.1%	0.194
Hispanic/Latinx							0.480
Yes	407	17.5%	4	10.8%	403	17.6%	
No	1484	63.8%	27	73.0%	1457	63.7%	
Unknown	278	12.0%	4	10.8%	274	12.0%	
Missing	157	6.7%	2	5.4%	155	6.8%	
Reporting Country							
United States	926	39.8%	19	51.4%	907	39.6%	0.148
Spain	247	10.6%	9	16.2%	241	10.5%	0.276
Russian Federation	140	6.0%	б	8.1%	137	6.0%	0.485
United Kingdom	95	4.1%	0	0.0%	95	4.2%	0.401
France	102	4.4%	1	2.7%	101	4.4%	>0.999
Italy	81	3.5%	0	0.0%	81	3.5%	0.638
Brazil	85	3.7%	1	2.7%	84	3.7%	>0.999
Iran, Islamic Republic of	53	2.3%	1	2.7%	52	2.3%	0.577
Belgium	48	2.1%	1	2.7%	47	2.1%	0.541
Argentina	49	2.1%	0	0.0%	49	2.1%	>0.999
Germany	46	2.0%	1	2.7%	45	2.0%	0.525
Turkey	41	1.8%	0	0.0%	41	1.8%	>0.999
Netherlands	32	1.4%	1	2.7%	31	1.4%	0.403
Canada	33	1.4%	1	2.7%	32	1.4%	0.413
Other	348	15.0%	2	5.4%	346	15.1%	0.100
Disease Type*							< 0.001
Crohn's Disease	1299	55.8%	9	16.2%	1293	56.5%	
Ulcerative Colitis	976	42.0%	30	81.1%	946	41.3%	
IRD-msnecified	45	1 9%		2 70%	44	1 0%	

TABLE 1. Demographic and Clinical Characteristics of IBD Patients on Tofacitinib Compared With Other IBD Therapies in the SECURE-IBD

N(Mein) $%$ (SD)         N(Mein)         <	Characteristic <sup>a,b</sup>	All Patien	All Patients on >1 Medication	L	Tofacitinih	Other	Other IBD Therany	
1290       55.5%       12       32.4%       1278       5         454       19.5%       12       32.4%       1278       5         454       19.5%       12       32.4%       442       1         454       19.5%       12       32.4%       442       1         454       19.5%       12       32.4%       442       1         513       22.1%       23       6.2%       1518       6         513       22.1%       2       3.4%       1518       2         120       6.4%       3       8.1%       147       2         130       6.6%       3       8.1%       120       2         131       6.6%       3       8.1%       120         132       5.2%       2       5.4%       130         130       5.6%       2       5.4%       130         14%       1       2.7%       3       3       147         150       2.4%       1       2.7%       38       13         151       1       2.7%       2.4%       13       2         153       1       2.7%       2.4%       13 <th></th> <th>N (Mean)</th> <th>% (SD)</th> <th></th> <th>% (SD)</th> <th>N (Mean)</th> <th>% (SD)</th> <th>) De</th>		N (Mean)	% (SD)		% (SD)	N (Mean)	% (SD)	) De
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$		(mart)		(marti)				
1290         55.5%         12 $32.4\%$ $1278$ $1278$ 454         19.5%         12 $32.4\%$ 142           454         19.5%         12 $32.4\%$ 147           496         21.3%         12 $32.4\%$ 442           5         13.5%         13         444           513         22.1%         9         24.3%         504           513         22.1%         9         24.3%         513           513         22.1%         9         24.3%         147           150         6.4%         3         8.1%         147           123         5.2%         2         5.4%         120           130         5.6%         2         5.4%         133           140         1.7%         0         0.0%         40           130         5.6%         2         5.4%         133           115         4.9%         1         2.7%         2.6%           33         1.1%         2.7%         2.6%         2.6%           33         1.1%         2.7%         2.6%         2.6%	IBD disease activity <sup>d,*</sup>							0.031
454 $19.5\%$ $12$ $32.4\%$ $442$ $496$ $21.3\%$ $12$ $32.4\%$ $441$ $496$ $21.3\%$ $12$ $32.4\%$ $441$ $151$ $66.3\%$ $5$ $12$ $32.4\%$ $481$ $151$ $66.3\%$ $2$ $32.4\%$ $481$ $151$ $66.3\%$ $2$ $32.4\%$ $187$ $150$ $6.4\%$ $3$ $8.1\%$ $147$ $150$ $6.4\%$ $3$ $8.1\%$ $147$ $120$ $6.4\%$ $3$ $8.1\%$ $147$ $120$ $6.6\%$ $3$ $8.1\%$ $147$ $130$ $5.6\%$ $2$ $5.4\%$ $113$ $115$ $4.9\%$ $2$ $5.4\%$ $113$ $30$ $1.7\%$ $0$ $0$ $0.2\%$ $313$ $1.4\%$ $0$ $0.2\%$ $0.2\%$ $310$ $1.7\%$ $0$ $0.2\%$ $0.2\%$	Remission	1290	55.5%	12	32.4%	1278	55.8%	
496 $21.3\%$ $12$ $32.4\%$ $484$ $5$ $13.5\%$ $187$ $484$ $513$ $22.1\%$ $5$ $13.5\%$ $187$ $513$ $22.1\%$ $5$ $13.5\%$ $187$ $513$ $22.1\%$ $23$ $62.2\%$ $147$ $513$ $22.1\%$ $3$ $8.1\%$ $147$ $120$ $6.4\%$ $3$ $8.1\%$ $147$ $120$ $6.6\%$ $3$ $8.1\%$ $120$ $130$ $5.6\%$ $3$ $8.1\%$ $120$ $130$ $5.6\%$ $3$ $8.1\%$ $120$ $115$ $4.9\%$ $2$ $5.4\%$ $113$ $115$ $4.9\%$ $2$ $5.4\%$ $113$ $30$ $1.7\%$ $0$ $0$ $0.0\%$ $310$ $1.7\%$ $0$ $0$ $0.0\%$ $310$ $1.7\%$ $0$ $0$ $0.0\%$ $310$ $1.1\%$ <td>Mild</td> <td>454</td> <td>19.5%</td> <td>12</td> <td>32.4%</td> <td>442</td> <td>19.3%</td> <td></td>	Mild	454	19.5%	12	32.4%	442	19.3%	
steroids $12$ $8.3\%$ $5$ $13.5\%$ $187$ $513$ $52.1\%$ $6.3\%$ $23$ $62.2\%$ $1518$ $513$ $22.1\%$ $9$ $24.3\%$ $504$ $150$ $6.4\%$ $3$ $8.1\%$ $147$ $120$ $6.4\%$ $3$ $8.1\%$ $147$ $130$ $5.6\%$ $2$ $5.4\%$ $120$ $130$ $5.6\%$ $2$ $5.4\%$ $120$ $130$ $5.6\%$ $2$ $5.4\%$ $120$ $115$ $4.9\%$ $2$ $5.4\%$ $120$ $33$ $1.4\%$ $2$ $5.4\%$ $113$ $33$ $1.4\%$ $2$ $5.4\%$ $113$ $33$ $1.4\%$ $2$ $5.4\%$ $113$ $33$ $1.4\%$ $2$ $5.4\%$ $113$ $33$ $1.4\%$ $2$ $5.4\%$ $2$ $33$ $1.4\%$ $2$ $2$ $2$	Moderate/Severe	496	21.3%	12	32.4%	484	21.1%	
	Concomitant systemic corticosteroids	192	8.3%	5	13.5%	187	8.2%	0.106
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Comorbidity summary score							>0.999
513 $22.1\%$ 9 $24.3\%$ 504rbid conditions120 $6.4\%$ 3 $8.1\%$ 147rbid conditions122 $5.2\%$ 2 $5.4\%$ 120rbid conditions130 $6.6\%$ 3 $8.1\%$ 150betes130 $5.6\%$ 2 $5.4\%$ 130betes115 $4.9\%$ 2 $5.4\%$ 133betes115 $4.9\%$ 2 $5.4\%$ 113hma115 $4.9\%$ 2 $5.6\%$ 2 $5.4\%$ hma115 $4.9\%$ 2 $2.5.6\%$ 133non115 $4.9\%$ $2.7\%$ $3.2.7\%$ $3.2.7\%$ refronic lung disease33 $1.4\%$ $1$ $2.7\%$ $3.66$ refronic lung disease30 $1.7\%$ $0$ $0.0\%$ $20$ refronic lung disease $3.1.7\%$ $1.7\%$ $2.7\%$ $3.66$ refronic lung disease $3.4\%$ $1$ $2.7\%$ $2.9\%$ orit of stroke $3.4\%$ $1$ $2.7\%$ $2.9\%$ orit of stroke $80$ $3.4\%$ $1$ $2.7\%$ $2.9\%$ orit liver disease $80$ $3.3\%$ $0.0\%$ $2.7\%$ $2.9\%$ orit liver disease $80$ $3.4\%$ $1$ $2.7\%$ $2.9\%$ orit volt $8.1\%$ $2.3\%$ $0.0\%$ $2.9\%$ $2.9\%$ orit volt $1.7\%$ $2.3\%$ $0.0\%$ $2.9\%$ orit volt $8.1\%$ $0.0\%$ $0.0\%$ $2.9\%$ orit volt $1.7\%$	0	1541	66.3%	23	62.2%	1518	66.3%	
150 $6.4\%$ $3$ $8.1\%$ $147$ rbid conditions122 $5.2\%$ $2$ $5.4\%$ $120$ rbid conditions133 $6.6\%$ $3$ $8.1\%$ $147$ diovascular disease133 $6.6\%$ $3$ $8.1\%$ $120$ betes130 $5.6\%$ $2$ $5.4\%$ $128$ betes115 $4.9\%$ $2$ $5.4\%$ $123$ hma115 $4.9\%$ $2$ $5.6\%$ $2$ $5.4\%$ hma115 $4.9\%$ $2$ $5.6\%$ $2$ $5.4\%$ hma117% $0$ $0$ $0.0\%$ $40$ er chronic lung disease $33$ $1.7\%$ $0$ $2$ $5.4\%$ er chronic lung disease $33$ $1.7\%$ $1$ $2.7\%$ $266$ er chronic lung disease $30$ $1.7\%$ $1$ $2.7\%$ $266$ er chronic lung disease $30$ $1.7\%$ $1$ $2.7\%$ $266$ er concritic $33$ $1.7\%$ $1$ $2.7\%$ $266$ er concritic $33$ $1.7\%$ $1$ $2.7\%$ $266$ onic renal disease $30$ $1.3\%$ $1$ $2.7\%$ $266$ onic liver disease $80$ $3.4\%$ $1$ $2.7\%$ $29$ onic liver disea	1	513	22.1%	6	24.3%	504	22.0%	
122 $5.2\%$ $2$ $5.4\%$ $120$ rbid conditions153 $6.6\%$ 3 $8.1\%$ $150$ diovascular disease153 $6.6\%$ 3 $8.1\%$ $150$ betes130 $5.6\%$ 2 $5.4\%$ $128$ hma115 $4.9\%$ 2 $5.4\%$ $113$ PD40 $1.7\%$ 0 $0.0\%$ $40$ er chronic lung disease33 $1.4\%$ $12.7\%32er chronic lung disease331.1.7\%616.2\%266oric rol disease301.7\%12.7\%32oric rol disease301.3\%12.7\%290oric rol disease542.3\%12.7\%290oric rol disease803.4\%12.7\%290oric rol disease542.3\%0.0\%900900oric rol disease542.3\%12.7\%290oric rol disease542.3\%12.7\%290oric rol disease2931.2.6\%32003100oric rol disease2931.2.6\%3290310oric rol disease12.3\%12.7\%290oric rol disease2931.2.6\%322.2\%290oric rol disease102.3\%102.7\%2901 < 301.2\%<$	2	150	6.4%	С	8.1%	147	6.4%	
thid conditions divorscular disease 153 $6.6\%$ 3 $8.1\%$ 150 betes 130 $5.6\%$ 2 $5.4\%$ 128 htma 115 $4.9\%$ 2 $5.4\%$ 113 htma 115 $4.9\%$ 2 $5.4\%$ 113 PD $2.7\%$ 2 $5.4\%$ 113 er chronic lung disease 33 $1.4\%$ 1 $2.7\%$ 40 er chronic lung disease 3.3 $1.4\%$ 1 $2.7\%$ 20 betes 3.3 $1.4\%$ 1 $2.7\%$ 20 introver and disease 54 $2.3\%$ 1 $2.7\%$ 29 onic renal disease 80 $3.4\%$ 1 $2.7\%$ 29 onic renal disease 80 $3.4\%$ 0 $0.0\%$ 88 htts: 1.2.6\% 2.0\% 20 htts: 1.2.6\% 20 htts: 1.2.7\% 20 htts: 1.2.6\% 20 htts: 1.2.5\% 20 htts:	≥3	122	5.2%	2	5.4%	120	5.2%	
divoracular disease153 $6.6\%$ 3 $8.1\%$ $150$ betes130 $5.6\%$ 2 $5.4\%$ $150$ betes115 $4.9\%$ 2 $5.4\%$ $133$ betes130 $5.6\%$ 2 $5.4\%$ $13$ betes130 $5.6\%$ 2 $5.4\%$ $13$ betes130 $5.6\%$ 2 $5.4\%$ $13$ betes3 $1.7\%$ 00 $0.0\%$ $40$ PD $33$ $1.7\%$ 00 $0.0\%$ $40$ PD $33$ $1.7\%$ $0$ $0$ $0.0\%$ $40$ PD $33$ $1.7\%$ $0$ $0$ $0.0\%$ $40$ PD $33$ $1.7\%$ $0$ $0.0\%$ $32$ cert $33$ $1.7\%$ $1.7\%$ $2.7\%$ $32$ correlation $30$ $1.7\%$ $3.4\%$ $1.7\%$ $2.7\%$ $36$ correlation $30$ $1.7\%$ $3.4\%$ $1.7\%$ $2.7\%$ $36$ correlation $30$ $1.2.6\%$ $3.4\%$ $1$ $2.7\%$ $39$ correlation $233$ $12.6\%$ $3.4\%$ $31.9\%$ $32.7\%$ $32.7\%$ correlation $33$ $1.5\%$ $3.4\%$ $3.1\%$ $3.1\%$ $3.1\%$ correlation $30$ $3.4\%$ $3.4\%$ $3.1\%$ $3.7\%$ $3.7\%$ correlation $30$ $3.2\%$ $3.2\%$ $3.2\%$ $3.2\%$ $3.2\%$ correlation $30$ $3.2\%$ $3.2\%$ $3.2\%$ $3.2\%$	Comorbid conditions							
betes 130 $5.6\%$ 2 $5.4\%$ 128 hm 115 $4.9\%$ 2 $5.4\%$ 113 PD $0.0\%$ $4.0$ $0.0\%$ $4.0$ er chronic lung disease 33 $1.4\%$ $1.7\%$ $0 0 0.0\%$ $4.0$ er chronic lung disease 3.3 $1.4\%$ $1 2.7\%$ $2.66$ $3.2$ bettension 2.72 $11.7\%$ $6 16.2\%$ $2.66$ $3.2$ tory of stroke 3.0 $1.3\%$ $1 1.7\%$ $1 2.7\%$ $2.9$ oric renal disease 5.4 $2.3\%$ $1 1 2.7\%$ $2.9$ onic renal disease $8.0 3.4\%$ $1 2.7\%$ $2.9$ onic liver disease $8.0 3.4\%$ $0 0.0\%$ $88$ $1.\%$ $2.90$ at smoker $88 3.3\%$ $0 0 0.0\%$ $88$ $1.9\%$ $2.90$ transfer $1.5.9\%$ $1.2.6\%$ $3 8.1\%$ $2.90$ 1.5.9% $1.0 2.7%$ $3.60$ $1.5.9%$ $1.0 2.7%$ $3.601 1.5.9%$ $1.0 2.7%$ $3.60$ $1.5.9%$ $1.0 2.7%$ $3.601 1.5.9%$ $1.0 0.0%$ $3.60$ $1.5.9%$ $1.5.9%$ $1.50%$ $1.5$	Cardiovascular disease	153	6.6%	3	8.1%	150	6.6%	0.732
hma $115$ $4.9\%$ $2$ $5.4\%$ $113$ PD $40$ $1.7\%$ $0$ $0.0\%$ $40$ PD $33$ $1.4\%$ $1$ $2.7\%$ $32$ Potencium disease $33$ $1.7\%$ $6$ $16.2\%$ $266$ Sertension $272$ $11.7\%$ $6$ $16.2\%$ $266$ Sertension $272$ $11.7\%$ $1$ $2.7\%$ $33$ Sertension $30$ $1.7\%$ $1$ $2.7\%$ $266$ Sertension $30$ $1.3\%$ $1$ $2.7\%$ $266$ Sertension $30$ $1.3\%$ $1$ $2.7\%$ $29$ Sertension $30$ $1.3\%$ $1$ $2.7\%$ $29$ Sertension $33$ $1.2.6\%$ $3.4\%$ $1$ $2.7\%$ $29$ Sertension $293$ $12.6\%$ $3$ $60.0\%$ $88$ Sertension $233$ $12.6\%$ $23$ $62.2\%$ $1501$ It smoker $88$ $3.8\%$ $0$ $0.0\%$ $360$ Sertension $370$ $15.9\%$ $10$ $27.0\%$ $360$ Sertension $370$ $15.9\%$ $10$ $27.0\%$ $360$	Diabetes	130	5.6%	2	5.4%	128	5.6%	>0.999
PD $17\%$ $0$ $0.0\%$ $40$ er chronic lung disease $33$ $1.4\%$ $1$ $2.7\%$ $32$ er chronic lung disease $33$ $1.4\%$ $1$ $2.7\%$ $32$ bertension $272$ $11.7\%$ $6$ $16.2\%$ $266$ cer $39$ $1.7\%$ $1$ $2.7\%$ $36$ corr $39$ $1.7\%$ $1$ $2.7\%$ $266$ corr $30$ $1.3\%$ $1$ $2.7\%$ $266$ corr $30$ $1.3\%$ $1$ $2.7\%$ $29$ onic renal disease $54$ $2.3\%$ $1$ $2.7\%$ $29$ onic liver disease $80$ $3.4\%$ $1$ $2.7\%$ $29$ onic liver disease $80$ $3.4\%$ $1$ $2.7\%$ $29$ onic liver disease $80$ $3.4\%$ $0$ $0.0\%$ $88$ $12.6\%$ $3.8\%$ $0$ $0$ $0.0\%$ $88$ $12.6\%$ $23$ $62.2\%$ $150$ $290$ $12.30$ $15.9\%$ $10$ $0.0\%$ $360$ $1<230$ $10$ $27.0\%$ $360$ $1>=30$ $10$ $10.0\%$ $360$	Asthma	115	4.9%	2	5.4%	113	4.9%	0.705
er chronic lung disease33 $1.4\%$ 1 $2.7\%$ 32bertension $272$ $11.7\%$ $6$ $16.2\%$ $266$ bertension $272$ $11.7\%$ $6$ $16.2\%$ $266$ bertension $39$ $1.7\%$ $1$ $2.7\%$ $38$ cer $30$ $1.3\%$ $1$ $2.7\%$ $29$ cory of stroke $54$ $2.3\%$ $1$ $2.7\%$ $29$ onic renal disease $80$ $3.4\%$ $1$ $2.7\%$ $29$ onic liver disease $80$ $3.4\%$ $1$ $2.7\%$ $53$ onic liver disease $80$ $3.4\%$ $0$ $0$ $0.0\%$ er comorbidity $293$ $12.6\%$ $3$ $8.1\%$ $290$ er comorbidity $293$ $12.6\%$ $3.8\%$ $0$ $0.0\%$ $88$ $12.6\%$ $23$ $62.2\%$ $1501$ $1501$ $1<230$ $15.9\%$ $10$ $27.0\%$ $360$ $1>=30$ $370$ $15.9\%$ $10$ $27.0\%$ $360$	COPD	40	1.7%	0	0.0%	40	1.7%	>0.999
certansion $272$ $11.7\%$ $6$ $16.2\%$ $266$ cer $39$ $1.7\%$ $1$ $2.7\%$ $38$ cer $30$ $1.3\%$ $1$ $2.7\%$ $38$ onic renal disease $54$ $2.3\%$ $1$ $2.7\%$ $29$ onic liver disease $80$ $3.4\%$ $0$ $0.0\%$ $88$ $12.6\%$ $293$ $12.6\%$ $3$ $8.1\%$ $290$ on subdity $293$ $12.6\%$ $3$ $8.1\%$ $290$ $1$ smoker $88$ $3.8\%$ $0$ $0.0\%$ $88$ $12.6\%$ $10$ $2.7\%$ $290$ $81\%$ $290$ $12.6\%$ $3.8\%$ $0$ $0.0\%$ $290$ $88$ $12.6\%$ $23$ $62.2\%$ $1501$ $1501$ $1<230$ $15.9\%$ $10$ $27.0\%$ $360$ $100$ $10$ $27.0\%$ $1501$ $1000$	Other chronic lung disease	33	1.4%	1	2.7%	32	1.4%	0.413
cer39 $1.7\%$ 1 $2.7\%$ 38fory of stroke30 $1.3\%$ 1 $2.7\%$ 38onic renal disease54 $2.3\%$ 1 $2.7\%$ 29onic liver disease54 $2.3\%$ 1 $2.7\%$ 53onic liver disease80 $3.4\%$ 1 $2.7\%$ 53onic liver disease80 $3.4\%$ 1 $2.7\%$ 59er comorbidity293 $12.6\%$ 381.9\%290nt smoker88 $3.8\%$ 0 $0.0\%$ 88I smoker83 $3.8\%$ 0 $0.0\%$ 88I smoker15011 $0.0\%$ $0.0\%$ 360 $1 > = 30$ $370$ $15.9\%$ $10$ $0.0\%$ $3.60$ $1 > 5.5\%$ $15.9\%$ $10$ $0.0\%$ $3.60$	Hypertension	272	11.7%	9	16.2%	266	11.6%	0.433
tory of stroke30 $1.3\%$ 1 $2.7\%$ 29onic renal disease $54$ $2.3\%$ $1$ $2.7\%$ $29$ onic liver disease $80$ $3.4\%$ $1$ $2.7\%$ $79$ onic liver disease $80$ $3.4\%$ $1$ $2.7\%$ $79$ or combidity $293$ $12.6\%$ $3$ $8.1\%$ $290$ er comorbidity $293$ $12.6\%$ $3$ $8.1\%$ $290$ nt smoker $88$ $3.8\%$ $0$ $0.0\%$ $88$ I smoker $88$ $3.8\%$ $0$ $0.0\%$ $88$ I smoker $1524$ $65.5\%$ $23$ $62.2\%$ $1501$ I > 30 $370$ $15.9\%$ $10$ $27.0\%$ $360$	Cancer	39	1.7%	1	2.7%	38	1.7%	0.468
onic rend disease $54$ $2.3\%$ $1$ $2.7\%$ $53$ onic liver disease $80$ $3.4\%$ $1$ $2.7\%$ $53$ onic liver disease $80$ $3.4\%$ $1$ $2.7\%$ $79$ er conorbidity $293$ $12.6\%$ $3$ $8.1\%$ $290$ at smoker $88$ $3.8\%$ $0$ $0.0\%$ $88$ I smoker $88$ $3.8\%$ $0$ $0.0\%$ $88$ I smoker $88$ $3.8\%$ $0$ $0.0\%$ $88$ I smoker $1524$ $65.5\%$ $23$ $62.2\%$ $1501$ I > $30$ $370$ $15.9\%$ $10$ $27.0\%$ $360$ $1050\%$ $10$ $27.0\%$ $360$ $100\%$ $100\%$	History of stroke	30	1.3%	1	2.7%	29	1.3%	0.384
onic liver disease $80$ $3.4\%$ $1$ $2.7\%$ $79$ er comorbidity $293$ $12.6\%$ $3$ $8.1\%$ $290$ at smoker $88$ $3.8\%$ $0$ $0.0\%$ $88$ 1 smoker $1524$ $65.5\%$ $23$ $62.2\%$ $1501$ 1 >= $30$ $370$ $15.9\%$ $10$ $27.0\%$ $360$ $1 > 500$ $10$ $27.0\%$ $360$ $1 > 500$ $10^{600}$ $4^{600}$ $4^{600}$ $4^{600}$	Chronic renal disease	54	2.3%	1	2.7%	53	2.3%	0.584
er comorbidity $293$ 12.6% $3$ 8.1% 290 at smoker $88$ $3.8\%$ $0$ $0.0\%$ $88$ I < 30 $1524$ $65.5\%$ $23$ $62.2\%$ $1501$ 1>=30 $370$ $15.9%$ $10$ $27.0%$ $36010$ $10$ $0.0%$ $360$	Chronic liver disease	80	3.4%	1	2.7%	79	3.5%	>0.999
at smoker     88 $3.8\%$ 0 $0.0\%$ 88       I<30	Other comorbidity	293	12.6%	3	8.1%	290	12.7%	0.616
$I < 30$ $I \leq 24$ $65.5\%$ $23$ $62.2\%$ $I501$ $I >= 30$ $370$ $I \leq 9\%$ $I 0$ $27.0\%$ $360$ $310$ $I \leq 9\%$ $I 0$ $27.0\%$ $360$	Current smoker	88	3.8%	0	0.0%	88	3.8%	0.400
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	BMI							0.122
30 370 15.9% 10 27.0% 360 423 18.6% 4 10.0% 350	BMI<30	1524	65.5%	23	62.2%	1501	65.6%	
12.2 18 60% 1 10 00% 1.20	BMI>=30	370	15.9%	10	27.0%	360	15.7%	
422 10.070 4 10.070 420	Missing	432	18.6%	4	10.8%	428	18.7%	

# <sup>a</sup>Unless otherwise specified, percentages do not include missing values or "unknown." For all characteristics, unless noted above, less than 4% of data were missing and unknown, respectively, for each category. <sup>b</sup>Percentages and n from each subcategory may not add up to the exact number of total reported cases due to missing values and/or non-mutually exclusive variables. <sup>c</sup>*P*-values for tests comparing variables between toffacitinib and other medications groups <sup>d</sup>By physician global assessment (PGA) at time of COVID-19 infection \*Statistically significant association.

Abbreviations: CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease.

# TABLE 1. Continued

## METHODS

The Surveillance Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease (SECURE-IBD) is a global, web-based, collaborative registry established in March 2020 to understand COVID-19 outcomes in IBD patients, including the impact of immunosuppression.<sup>6</sup> The collection and categorization of data have been reported previously.<sup>6</sup>

Using data reported though September 2020, we compared characteristics and COVID-19 outcomes of IBD patients on tofacitinib and those on other medications. We determined the proportion of patients with severe COVID-19, defined as a composite of intensive care unit (ICU) admission, mechanical ventilation, and/or death. In June 2020, we addended the SECURE-IBD data collection form to include questions pertaining to thrombotic complications. We compared the proportion of patients with thrombotic complications who were on tofacitinib with those on other IBD therapies. We performed bivariate analyses using  $\chi^2$  or Fisher exact test for categorial variables and Wilcoxon rank-sum or *t* test for continuous variables. *P* values  $\leq 0.05$  were considered statistically significant for all analyses. SAS version 9.3 (SAS Institute, Cary, North Carolina) was used for data preparation and analyses.

As SECURE-IBD collects only de-identified data, the UNC-Chapel Hill Office for Human Research Ethics has determined that the storage and analysis of de-identified data for this project does not constitute human subjects research.

## RESULTS

Of 2326 patients who were on  $\ge 1$  IBD medication in the SECURE-IBD registry, 37 (1.6%) were treated with tofacitinib; 17 (45.9%) and 20 (54.1%) patients were on  $\ge 20$  and < 20 mg total daily dose of tofacitinib, respectively. Baseline demographic and clinical characteristics of patients on tofacitinib compared with those on other medications are reported in the Table 1. Thirty (81.1%) patients in the tofacitinib group had UC compared with 946 (41.3%) patients on other IBD medications

(P < 0.001). Significantly fewer patients were in remission in the tofacitinib group compared with those on other medications (32.4% vs 55.8%, P = 0.03). All other baseline demographic and clinical characteristics were comparable between the 2 groups.

With respect to COVID-19 outcomes, there were no significant differences between tofacitinib-treated patients and other patients in the occurrence of hospitalization (21.6% vs 23.3%), admission to the ICU (5.4% vs 4.5%), and severe COVID-19 (6.2% in both groups, Table 2). In the subgroup of patients on tofacitinib for whom information on thrombotic events were available (n = 19), none experienced a thrombotic event. Among those on other IBD medications, thrombotic events occurred in 9 of 1270 (0.7%).

## DISCUSSION

We describe characteristics and outcomes of COVID-19 in 37 patients with IBD treated with tofacitinib compared with other medications in the SECURE-IBD registry. Overall, we found no difference in COVID-19 outcomes between the 2 groups.

Our findings are consistent with previous descriptive reports of patients on JAKi for UC and other immune-mediated disease; although in each of these studies, COVID-19 outcomes are reported jointly among the few patients on JAKi along with other immunosuppression.<sup>6-9</sup> In a case report of a 33-year-old woman with UC on tofacitinib, respiratory symptoms resolved in 5 days, and the patient recovered completely in 2 weeks with no change to tofacitinib treatment.<sup>10</sup>

In addition, although patients with COVID-19 may experience thrombotic complications, and tofacitinib at the higher dose has been associated with venous thromboembolism,<sup>5</sup> none of the tofacitinib-treated patients in SECURE-IBD experienced thrombotic complications. Overall, these early data should be viewed as cautiously reassuring to patients and providers while we await larger studies and more granular analyses to parse out the impact of JAKi on COVID-19 outcomes.

TABLE 2. COVID-19	Outcomes	Among	IBD	Patients	on	Tofacitinib	Compared	With	Other	IBD	Therapies	in 1	the
SECURE-IBD Registry													

	All Patien	ts on ≥1 Medicatio	on				
Outcome	n (%)		Tofaciti	nib, n (%)	Other IBI	) therapy, n (%)	Р
Outpatient care	1753	75.4%	29	78.4%	1724	75.3%	0.668
Hospitalization	542	23.3%	8	21.6%	534	23.3%	0.807
ICU admission	106	4.6%	2	5.4%	104	4.5%	0.685
Mechanical ventilation	77	3.3%	1	2.7%	76	3.3%	>0.999
Death	61	2.6%	1	2.7%	60	2.6%	>0.999
Severe COVID-19 outcomes <sup>a</sup>	144	6.2%	2	5.4%	142	6.2%	>0.999

aIncludes composite of ICU admission, mechanical ventilation, and death.

Strengths of this study include the use of a large, international registry of adult and pediatric IBD patients with diverse characteristics and outcomes. Limitations include the small number of patients on tofacitinib and even fewer outcomes precluding adjusted analyses; however, most demographic and clinical characteristics were comparable between tofacitinib-treated and other IBD patients. The only notable differences were the higher proportion of tofacitinib-treated patients with UC and active IBD. This is likely due to the real-world use of tofacitinib in moderate-severely active UC refractory to tumor necrosis factor antagonists.<sup>2</sup> There are also risks of reporting bias and missing data in this voluntary registry.

In summary, in our descriptive analysis, characteristics and COVID-19 outcomes among IBD patients on tofacitinib were comparable to those on other IBD medications. Future larger studies of patients on tofacitinib are needed to understand clinical implications.

**Data Availability:** The data underlying this article are available in the article and in its online supplementary material.

## REFERENCES

- Richardson S, Hirsch JS, Narasimhan M, et al.; the Northwell COVID-19 Research Consortium. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York city area. *Jama*. 2020;323:2052–2059.
- Sandborn WJ, Su C, Sands BE, et al.; OCTAVE Induction 1, OCTAVE Induction 2, and OCTAVE Sustain Investigators. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376:1723–1736.
- Lee JS, Shin EC. The type I interferon response in COVID-19: implications for treatment. Nat Rev Immunol. 2020;20:585–586.
- Bronte V, Ugel S, Tinazzi E, et al. Baricitinib restrains the immune dysregulation in severe COVID-19 patients. J Clin Invest. 2020.
- Pfizer. XELJANZ (Tofacitinib): Increased Risk of Pulmonary Embolism and Mortality in Rheumatoid Arthritis Patients Receiving 10 mg Twice Daily in a Clinical Trial. 2019.
- Brenner EJ, Ungaro RC, Gearry RB, et al. Corticosteroids, but not TNF antagonists, are associated with adverse COVID-19 outcomes in patients with inflammatory bowel diseases: results from an international registry. *Gastroenterology*. 2020.
- Lukin DJ, Kumar A, Hajifathalian K, et al.; Jill Roberts Center Study Group Study Group; Weill Cornell Medicine-Gastrointestinal Study Group. Baseline disease activity and steroid therapy stratify risk of COVID-19 in patients with inflammatory bowel disease. *Gastroenterology*. 2020;159:1541–1544.e2.
- Gianfrancesco M, Hyrich KL, Al-Adely S, et al.; COVID-19 Global Rheumatology Alliance. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. *Ann Rheum Dis.* 2020;79:859–866.
- Reinisch W, Rubin D, Zhou X, et al. Evaluation of patient characteristics and clinical outcomes among SARS-CoV-2 diagnosed patients with and without UC treated with systemic therapies: a retrospective cohort study using US Optum® COVID-19 EHR data. Am J Gastroenterol. 2020.
- Jacobs J, Clark-Snustad K, Lee S. Case report of a SARS-CoV-2 infection in a patient with ulcerative colitis on tofacitinib. *Inflamm Bowel Dis.* 2020;26:e64.